Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Total 13F shares
-
5,839,518
-
Share change
-
+3,383,368
-
Total reported value
-
$144,771,494
-
Price per share
-
$24.93
-
Number of holders
-
40
-
Value change
-
+$81,538,555
-
Number of buys
-
21
-
Number of sells
-
17
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q3 2019
As of 30 Sep 2019,
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,839,518 shares.
The largest 10 holders included
Capital Research Global Investors, SC US (TTGP), LTD., Capital International Investors, Alphabet Inc., Capital World Investors, VANGUARD GROUP INC, BlackRock Inc., MANUFACTURERS LIFE INSURANCE COMPANY, THE, GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This page lists
40
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.